trending Market Intelligence /marketintelligence/en/news-insights/trending/ibaML3xlLKbJ1osNpjzSGw2 content esgSubNav
In This List

Roche agrees to acquire genetic code analysis enzyme from Codexis

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Roche agrees to acquire genetic code analysis enzyme from Codexis

Roche Holding AG agreed to acquire worldwide rights of Codexis Inc.'s EvoT4, an enzyme that is used to analyze a patient's genetic code and how their cells express their genes as proteins.

EvoT4 was developed using Codexis' proprietary protein engineering platform CodeEvolver.

Redwood City, Calif.-based Codexis is a protein engineering company and develops proteins for manufacturing pharmaceuticals, fine chemicals and industrial enzymes.

Financial details of the agreement were not disclosed.